Remco van de Leigraad from the Janssen Vaccine Department, highlights the team’s efforts in developing robust methods for evaluating drug stability and efficacy, particularly against pathogens like extraintestinal E. coli and Staphylococcus aureus. Covered are the intricacies of testing for various stress conditions, including oxidation, and emphasizes the importance of high-throughput automation to improve efficiency and accuracy in their analyses.

In his presentation, van de Leigaard introduces the analytical development team and the range of instruments they utilize, such as LC-MS, MALDI-TOF, and CE. He shares insights into the methodological advancements achieved through automation and innovative software applications, which allow for faster and more comprehensive peptide mapping and analysis. The presentation also delves into the challenges posed by bacterial pathogens, particularly Staphylococcus aureus, and the strategies employed to overcome these hurdles. Through detailed examples, he shows the team’s success in reducing analysis time and enhancing data acquisition processes, ultimately aiming to develop effective vaccines against severe bacterial infections.